Edition:
United States

Ardelyx Inc (ARDX.OQ)

ARDX.OQ on NASDAQ Stock Exchange Global Market

5.80USD
10:54am EST
Change (% chg)

$-0.05 (-0.85%)
Prev Close
$5.85
Open
$5.90
Day's High
$5.90
Day's Low
$5.75
Volume
7,915
Avg. Vol
144,704
52-wk High
$15.40
52-wk Low
$4.05

Latest Key Developments (Source: Significant Developments)

Ardelyx Says Co Had About $134 Million In Cash
Monday, 8 Jan 2018 08:25am EST 

Jan 8 (Reuters) - Ardelyx Inc ::ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 .  Full Article

Ardelyx Successfully Completes T3mpo-3 Safety Extension Study Of Tenapanor For Ibs-C
Wednesday, 3 Jan 2018 06:30am EST 

Jan 3 (Reuters) - Ardelyx Inc ::ARDELYX SUCCESSFULLY COMPLETES T3MPO-3 SAFETY EXTENSION STUDY OF TENAPANOR FOR IBS-C.ARDELYX - ‍RESULTS FROM BOTH T3MPO-1 AND T3MPO-2 STUDIES, SAFETY DATA, SUPPORT CO'S PLANS TO SUBMIT FIRST NDA TO U.S. FDA FOR THE INDICATION IN H2 2018​.ARDELYX INC - RESULTS FROM T3MPO-3 SHOWED THAT TENAPANOR WAS WELL-TOLERATED AMONG 240 PATIENTS TREATED.  Full Article

Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Co for Tenapanor in China
Monday, 11 Dec 2017 06:00am EST 

Dec 11 (Reuters) - Ardelyx Inc ::Ardelyx announces license agreement with Shanghai Fosun Pharmaceutical Industrial Development Company Limited for Tenapanor in China.Ardelyx - under terms of agreement, Ardelyx will receive upfront payment of $12 million, is eligible to receive additional milestones of up to $113 million.Ardelyx Inc - Fosun Pharma will have exclusive rights to market and sell Tenapanor in China.Ardelyx - under terms of agreement, co will receive tiered royalty payments on net sales from Tenapanor ranging from mid-teens to 20 percent.Ardelyx Inc - agreement also provides Fosun Pharma rights to commercialize Tenapanor for other indications for which it is approved in United States.  Full Article

Ardelyx Inc says has decided to discontinue development of RDX7675 for treatment of hyperkalemia​​
Tuesday, 21 Nov 2017 06:30am EST 

Nov 21 (Reuters) - Ardelyx Inc :Ardelyx announces updated development path for its cardiorenal pipeline.Ardelyx - second registration study for tenapanor for treatment of hyperphosphatemia will begin enrolling shortly​.Ardelyx - second registration study for tenapanor will begin enrolling shortly after having received feedback from U.S. FDA on trial design.Ardelyx Inc - ‍in addition, co reported clinically meaningful potassium lowering activity from its study for RDX7675 for treatment of hyperkalemia​.Says ‍however, company also observed an unexpected side effect of decreased serum bicarbonate​.Ardelyx Inc - ‍believes the side effect will limit commercial potential of RDX7675 and, as a result, has decided to discontinue development of RDX7675​.Ardelyx inc - ‍ Ardelyx will shift its hyperkalemia efforts to RDX013, its earlier-stage, small-molecule program​.Ardelyx Inc - the change will result in a cash savings of about $40 million to Ardelyx over next two years, extending co's operating runway into 2019​.  Full Article

Ardelyx qtrly ‍net loss per common share $0.44​
Tuesday, 7 Nov 2017 06:30am EST 

Nov 7 (Reuters) - Ardelyx Inc ::Ardelyx reports third quarter 2017 operating results and clinical progress.Ardelyx Inc - ‍as of September 30, 2017, Ardelyx had total capital resources including cash, cash equivalents and short-term investments of $129.3 million​.Ardelyx qtrly ‍net loss per common share $0.44​.Ardelyx - phase 3 registration study hit statistical significance for primary endpoint and all secondary endpoints for t3mpo-2.  Full Article

Rock Springs Capital Management reports 5.02 pct passive stake in Ardelyx - SEC Filing
Thursday, 2 Nov 2017 10:25am EDT 

Nov 2 (Reuters) - Ardelyx Inc ::Rock Springs Capital Management LP​ reports 5.02 percent passive stake in Ardelyx Inc as of Oct 23 - SEC filing.  Full Article

Ardelyx announces Tenapanor reduces pain caused by IBS-C through inhibition of TRPV-1 signaling
Monday, 16 Oct 2017 08:01am EDT 

Oct 16 (Reuters) - Ardelyx Inc :Ardelyx announces Tenapanor reduces pain caused by IBS-c through inhibition of TRPV-1 signaling.Ardelyx - ‍data from preclinical studies have shown that tenapanor works to reduce abdominal pain caused by irritable bowel syndrome with constipation​.Ardelyx Inc - ‍moving forward to submit first nda to U.S. FDA for indication in second half of 2018​.  Full Article

Deerfield Management reports a 5.79 pct passive stake in Ardelyx‍​
Thursday, 31 Aug 2017 02:23pm EDT 

Aug 31 (Reuters) - Ardelyx Inc ::Deerfield Management LP reports a 5.79 pct passive stake in Ardelyx Inc <<>> as of August 21 - SEC filing ‍​.  Full Article

Ardelyx Inc qtrly loss per share $0.54‍​
Wednesday, 9 Aug 2017 06:30am EDT 

Aug 9 (Reuters) - Ardelyx Inc ::Ardelyx focuses resources on late-stage programs and reports second quarter 2017 operational results.Ardelyx inc - ‍T3MPO-2 phase 3 trial results of Tenapanor for IBS-C on track for early Q4​.Ardelyx inc - ‍RDX7675 onset-of-action data planned for Q4​.Ardelyx inc - ‍strategic review resulted in reduction in workforce of 28 percent, resulting in a remaining team of 76 employees​.Ardelyx inc qtrly loss per share $0.54‍​.Q2 earnings per share view $-0.64 -- Thomson Reuters I/B/E/S.  Full Article

Ardelyx reports successful phase 3 t3mpo-1 trial of tenapanor
Friday, 12 May 2017 06:30am EDT 

May 12 (Reuters) - Ardelyx Inc : :Ardelyx reports successful phase 3 t3mpo-1 trial of tenapanor in patients with IBS-C.Ardelyx reports successful phase 3 t3mpo-1 trial of tenapanor in patients with IBS-C.Ardelyx Inc - study achieves primary endpoint.Ardelyx Inc - tenapanor was well-tolerated, consistent with experience across previous clinical trials.Says it plans to assess the data alongside results from t3mpo-2, co's six-month phase 3 study.  Full Article

BRIEF-Ardelyx Says Co Had About $134 Million In Cash

* ARDELYX SAYS ON JAN 8, CO HAD ABOUT $134 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF DEC 31, 2017 Source text: (http://bit.ly/2AETXHu) Further company coverage: